On January 20, 2020 Evotec SE (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) reported an increase in its profitability guidance for the financial year 2019 after the preliminary completion of the latest evaluation of the Company’s financial performance (Press release, Evotec, JAN 20, 2020, View Source;announcements/ad-hoc-releases/p/evotec-se-increase-of-profitability-guidance-for-financial-year-2019-5901 [SID1234553340]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Based on the preliminary unaudited consolidated results for the financial year 2019, the Company now expects an increase of the adjusted Group EBITDA* by more than 25% (previously: improve by approx. 15%) for 2019 compared to previous year (2018: € 92.0 m). The positive adjustment of the guidance is primarily due to a strong operating performance in the fourth quarter of 2019 and unexpectedly high milestone revenues from long-term partnerships such as those with Celgene, Bayer and Sanofi in December 2019, which in particular needed to be clarified in terms of revenue recognition and the corresponding allocation to the 2019 or 2020 financial year.

All other elements of the Company’s financial guidance are confirmed.

*(EBITDA excludes contingent considerations, income from bargain purchase and excl. impairments on goodwill, other intangible and tangible assets as well as the total non-operating result)